CRBU
Live chart
What they do
Healthcare · Biotechnology
For information only · Important disclosures
Grades vs sector
No sector grades for CRBU yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.31 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.90 vs trailing $-1.08. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score -7.2 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $11.2M | $-148.1M | $-112.4M |
| 2024 | $10.0M | $-149.1M | $-143.1M |
| 2023 | $34.5M | $-102.1M | $-104.9M |
| 2022 | $13.9M | $-99.4M | $-97.4M |
| 2021 | $9.6M | $-66.9M | $-34.6M |
| 2020 | $12.4M | $-34.3M | $-33.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -7.0%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -0.31 | -0.24 | +21.7% |
| 2026-05-07 | -0.31 | -0.26 | +16.1% |
| 2026-03-05 | -0.32 | -0.28 | +12.9% |
| 2025-11-12 | -0.36 | -0.30 | +16.0% |
| 2025-08-12 | -0.42 | -0.35 | +16.7% |
| 2025-05-08 | -0.44 | -0.44 | +2.2% |
| 2025-03-10 | -0.40 | -0.39 | +3.3% |
| 2024-11-06 | -0.45 | -0.38 | +15.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.5M | -43.8% |
| 2026-03-31 | $2.4M | – |
| 2025-12-31 | $3.9M | – |
| 2025-09-30 | $2.2M | – |
| 2025-06-30 | $2.7M | – |
Analyst actions
PT $1
PT $1
PT $5
PT $11
Stats refreshed 2026-10-21 01:31:05 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026